ASMIDINE treatment for control of asthma symptoms

Overview

Asmidine is a novel polymeric asthma prevention treatment designed to control and prevent asthma exacerbations. It is a nasal spray that creates a protective surface film on the nasal mucosa, offering a safe and effective alternative to chemical drugs for asthma treatment.

Mechanism of Action

Asmidin is an innovative nasal spray designed to manage mild to moderate asthma. Its mechanism is based on a mechanical action, with no active chemical components, offering a safe and effective alternative.

Barrier effect: Asmidin forms a protective layer on the nasal mucosa. This barrier prevents allergens, pollutants and other asthma triggers from coming into contact with the respiratory mucosa, thereby preventing activation of the inflammatory response that leads to asthma attacks.

Cleansing of the nasal mucosa: Thanks to its osmotic properties, Asmidin attracts and eliminates contaminants present on the surface of the nasal mucosa, including the pro-inflammatory cytokines (TSLP, IL-25, IL-33) responsible for airway inflammation.

Reduced inflammation: By eliminating irritants and preventing inflammation from developing, Asmidin helps to restore the integrity of the nasal mucosa and prevent the exacerbation of asthmatic symptoms.

Benefits of Asmidin

• Protects against asthma triggers.
• Improves quality of life by reducing respiratory symptoms.
• Clinically proven efficacy, with no significant side effects

Asmidin is an innovative solution for asthma sufferers, complementing conventional treatments.

Clinical Efficacy

Adults : Asmidin vs Salbutamol

Study Design:

• 84-day, open-label, randomized study comparing Asmidine® nasal spray to Salbutamol inhaler
• 89 patients with partially controlled asthma, aged 18-70 years.

Treatment:

• Asmidine®: 2 nasal sprays per nostril, three times daily.
• Salbutamol: 1-2 oral puffs, three times daily.

Results:

• Peak Expiratory Flow Rate (PEFR):
  • Asmidine®: Increased from 198.0 to 345.5 L/min.
  • Salbutamol: Increased from 191.4 to 398.2 L/min.
• Forced Expiratory Volume (FEV1):
  • Asmidine®: Mean increase of 19%, 25%, and 19% at weeks 4, 8, and 12.
  • Salbutamol: Mean increase of 19%, 24%, and 17% at the same periods.
• Asthma Control (ACQ-5):
  • Asmidine®: Score reduced from 1.1 to 0.80.
  • Salbutamol: Score reduced from 0.90 to 0.60.
• Quality of Life (QOL):
  • Both treatments significantly improved QOL parameters.

Safety:

• No Serious Adverse Events (SAEs).
• Minor, transient side effects (e.g., stuffy nose, nausea).

See full publication (PDF)

Children

Asmidine has also been tested in children, where it has shown to increase lung function, improve quality of life, and reduce the need for additional medication. It has been found to be safe and effective, with no adverse effects reported.

See full publication (PDF)

Asmidine offers a new approach to asthma prevention and control. Its unique mechanism of action and proven clinical efficacy make it a promising alternative to traditional asthma treatments.

In conclusion, the clinical trials conducted on Asmidine have demonstrated promising results in both adult and pediatric populations. The trials showed that Asmidine significantly improved lung function and overall quality of life, effectively controlling bronchial asthma without any reported adverse effects.

Importantly, Asmidine demonstrated an efficacy similar to that of Salbutamol, a commonly used asthma medication. This is particularly noteworthy given that Asmidine operates through a unique mechanism of action, offering a new approach to asthma prevention and control.

These results suggest that Asmidine could be a safe and effective alternative to traditional chemical drugs for asthma treatment, providing a new option for patients who may not respond well to current treatments or who may be seeking a non-chemical approach to managing their asthma.